COSM
ACHAT TOTAL: 1116109 titres (~210000 USD)
- Insiders
- Siokas Grigorios
- Total bought
- $210,000
- Total sold
- —
- Last activity
- 2026-07-30
- Last synced
-
2026-08-04 10:23:03
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-03
COSM presents a meaningful multi-signal catalyst — a significant insider cluster buy (~$210k, 1.116M shares) by a key insider, coinciding with an AI-enabled platform launch and share buyback activity — generating a…
The first sentence of the analysis written for COSM on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 12.1% | 7.9% | 8.1% | 11.8% | 14.8% | |
| Ebit Margin | -25.3% | -27.9% | -33.1% | -18.1% | -7.6% | |
| Ebitda Margin | -23.2% | -25.6% | -32.0% | -17.7% | -6.8% | |
| Operating Profit Margin | -25.3% | -28.6% | -40.9% | -14.8% | -8.1% | |
| Pretax Profit Margin | -29.3% | -29.7% | -34.7% | -25.9% | -14.0% | |
| Continuous Operations Profit Margin | -29.3% | -29.7% | -34.7% | -27.5% | -14.2% | |
| Net Profit Margin | -29.3% | -29.7% | -34.7% | -27.5% | -14.2% | |
| Bottom Line Profit Margin | -29.3% | -41.1% | -48.3% | -127.0% | -27.7% | |
| Current Ratio | 1.003 | 0.989 | 1.505 | 2.577 | 1.331 | |
| Quick Ratio | 0.852 | 0.819 | 1.308 | 2.418 | 1.226 | |
| Solvency Ratio | -0.378 | -0.501 | -0.598 | -0.481 | -0.167 | |
| Cash Ratio | 0.019 | 0.012 | 0.158 | 0.954 | 0.010 | |
| Price To Earnings Ratio | -0.790 | -0.572 | -0.656 | -0.138 | -3.549 | |
| Price To Earnings Growth Ratio | 0.017 | 0.013 | 0.007 | -0.003 | 0.002 | |
| Forward Price To Earnings Growth Ratio | 0.017 | 0.013 | 0.007 | -0.003 | 0.002 | |
| Price To Earnings Diluted Ratio | -0.790 | -0.572 | -0.656 | -0.138 | -3.549 | |
| Price To Earnings Diluted Growth Ratio | 0.017 | 0.013 | 0.007 | -0.003 | 0.002 | |
| Price To Book Ratio | 0.819 | 0.522 | 0.468 | 0.222 | 12.638 | |
| Price To Sales Ratio | 0.231 | 0.235 | 0.316 | 0.175 | 0.984 | |
| Price To Free Cash Flow Ratio | -1.774 | -1.575 | -0.680 | -0.576 | -6.929 | |
| Price To Operating Cash Flow Ratio | -1.786 | -1.660 | -1.079 | -0.591 | -7.798 | |
| Debt To Assets Ratio | 0.305 | 0.218 | 0.188 | 0.177 | 0.549 | |
| Debt To Equity Ratio | 1.084 | 0.482 | 0.345 | 0.303 | 6.193 | |
| Debt To Capital Ratio | 0.520 | 0.325 | 0.256 | 0.233 | 0.861 | |
| Long Term Debt To Capital Ratio | 0.241 | 0.060 | 0.078 | 0.067 | 0.744 | |
| Financial Leverage Ratio | 3.554 | 2.214 | 1.832 | 1.716 | 11.287 | |
| Working Capital Turnover Ratio | -726.126 | 9.079 | 2.292 | 2.278 | 6.864 | |
| Operating Cash Flow Ratio | -0.221 | -0.300 | -0.643 | -0.684 | -0.237 | |
| Operating Cash Flow Sales Ratio | -0.129 | -0.142 | -0.293 | -0.295 | -0.126 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | 1.054 | 1.586 | 1.026 | 1.125 | |
| Debt Service Coverage Ratio | -0.939 | -1.318 | -1.877 | -0.806 | -0.232 | |
| Interest Coverage Ratio | -6.307 | -15.356 | -25.195 | -1.885 | -1.266 | |
| Short Term Operating Cash Flow Coverage Ratio | -0.625 | -0.808 | -1.901 | -1.849 | -0.532 | |
| Operating Cash Flow Coverage Ratio | -0.423 | -0.653 | -1.259 | -1.237 | -0.262 | |
| Capital Expenditure Coverage Ratio | -151.731 | -18.458 | -1.706 | -38.819 | -7.970 | |
| Dividend Paid And Capex Coverage Ratio | -151.731 | -1.167 | -1.706 | -38.819 | -7.970 | |
| Dividend Payout Ratio | 0.000 | -0.383 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.266 | -1.747 | -1.493 | -0.008 | -21.530 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 12.1% | ▲4.2% | ▲1.1% |
| Ebit Margin | -25.3% | ▲2.6% | ▼-2.9% |
| Ebitda Margin | -23.2% | ▲2.4% | ▼-2.2% |
| Operating Profit Margin | -25.3% | ▲3.2% | ▼-1.8% |
| Pretax Profit Margin | -29.3% | ▲0.4% | ▼-2.6% |
| Continuous Operations Profit Margin | -29.3% | ▲0.4% | ▼-2.2% |
| Net Profit Margin | -29.3% | ▲0.4% | ▼-2.2% |
| Bottom Line Profit Margin | -29.3% | ▲11.8% | ▲25.4% |
| Current Ratio | 1.003 | ▲0.015 | ▼-0.478 |
| Quick Ratio | 0.852 | ▲0.033 | ▼-0.473 |
| Solvency Ratio | -0.378 | ▲0.124 | ▲0.047 |
| Cash Ratio | 0.019 | ▲0.006 | ▼-0.212 |
| Price To Earnings Ratio | -0.790 | ▼-0.219 | ▲0.350 |
| Price To Earnings Growth Ratio | 0.017 | ▲0.005 | ▲0.010 |
| Forward Price To Earnings Growth Ratio | 0.017 | ▲0.005 | ▲0.010 |
| Price To Earnings Diluted Ratio | -0.790 | ▼-0.219 | ▲0.350 |
| Price To Earnings Diluted Growth Ratio | 0.017 | ▲0.005 | ▲0.010 |
| Price To Book Ratio | 0.819 | ▲0.296 | ▼-2.115 |
| Price To Sales Ratio | 0.231 | ▼-0.004 | ▼-0.157 |
| Price To Free Cash Flow Ratio | -1.774 | ▼-0.199 | ▲0.533 |
| Price To Operating Cash Flow Ratio | -1.786 | ▼-0.126 | ▲0.797 |
| Debt To Assets Ratio | 0.305 | ▲0.087 | ▲0.018 |
| Debt To Equity Ratio | 1.084 | ▲0.602 | ▼-0.598 |
| Debt To Capital Ratio | 0.520 | ▲0.195 | ▲0.081 |
| Long Term Debt To Capital Ratio | 0.241 | ▲0.181 | ▲0.003 |
| Financial Leverage Ratio | 3.554 | ▲1.340 | ▼-0.567 |
| Working Capital Turnover Ratio | -726.126 | ▼-735.205 | ▼-585.003 |
| Operating Cash Flow Ratio | -0.221 | ▲0.079 | ▲0.196 |
| Operating Cash Flow Sales Ratio | -0.129 | ▲0.012 | ▲0.068 |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | ▼-0.048 | ▼-0.153 |
| Debt Service Coverage Ratio | -0.939 | ▲0.379 | ▲0.096 |
| Interest Coverage Ratio | -6.307 | ▲9.049 | ▲3.695 |
| Short Term Operating Cash Flow Coverage Ratio | -0.625 | ▲0.183 | ▲0.518 |
| Operating Cash Flow Coverage Ratio | -0.423 | ▲0.230 | ▲0.344 |
| Capital Expenditure Coverage Ratio | -151.731 | ▼-133.272 | ▼-107.994 |
| Dividend Paid And Capex Coverage Ratio | -151.731 | ▼-150.564 | ▼-111.452 |
| Dividend Payout Ratio | 0.000 | ▲0.383 | ▲0.077 |
| Enterprise Value Multiple | -2.266 | ▼-0.519 | ▲3.143 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $15.1M | $12.8M | $16.9M | $8.8M | $55.3M | |
| Enterprise value | $34.3M | $24.3M | $25.5M | $68K | $82.2M | |
| EV / Sales | 0.53x | 0.45x | 0.48x | 0.00x | 1.46x | |
| EV / Op. cash flow | -4.07x | -3.15x | -1.63x | -0.01x | -11.58x | |
| EV / Free cash flow | -4.04x | -2.99x | -1.03x | -0.00x | -10.29x | |
| EV / EBITDA | -2.27x | -1.75x | -1.49x | -0.01x | -21.53x | |
| Net debt / EBITDA | -1.27x | -0.83x | -0.50x | 0.98x | -7.03x | |
| Current ratio | 1.00x | 0.99x | 1.50x | 2.58x | 1.33x | |
| Income quality | 0.44x | 0.48x | 0.84x | 1.07x | 0.89x | |
| Graham net-net | -$1 | -$1 | -$1 | $6 | -$31 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 105.9% | 101.5% | |
| Interest burden | 115.9% | 106.7% | 104.9% | 143.6% | 183.9% | |
| Working capital | $116K | -$296K | $12.3M | $34.3M | $9.9M | |
| Invested capital | $19.5M | $17.9M | $31.6M | $37.9M | $13.3M | |
| Return on assets | -29.2% | -29.8% | -28.1% | -20.3% | -16.1% | |
| Operating ROA | -27.6% | -25.8% | -32.6% | -12.7% | -9.7% | |
| Return on tangible assets | -33.1% | -34.8% | -31.8% | -20.5% | -16.3% | |
| Return on equity | -103.9% | -66.0% | -51.4% | -34.9% | -181.8% | |
| Return on invested capital | -40.4% | -40.6% | -43.5% | -13.8% | -13.7% | |
| Return on capital employed | -60.8% | -54.4% | -52.4% | -16.1% | -23.2% | |
| Earnings yield | -126.9% | -126.3% | -109.9% | -157.3% | -14.4% | |
| Free cash flow yield | -56.4% | -63.5% | -147.0% | -173.5% | -14.4% | |
| Capex / Op. cash flow | -0.7% | -5.4% | -58.6% | -2.6% | -12.5% | |
| Capex / Depreciation | 4.1% | 33.5% | 1492.2% | 202.8% | 198.0% | |
| Capex / Sales | 0.1% | 0.8% | 17.2% | 0.8% | 1.6% | |
| SG&A / Sales | 34.5% | 22.2% | 47.9% | 26.3% | 22.1% | |
| R&D / Sales | 0.8% | 1.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 3.5% | 3.1% | 1.1% | 0.0% | 10.5% | |
| Intangibles / Total assets | 11.6% | 14.3% | 11.6% | 1.0% | 1.0% | |
| Days sales outstanding | 126d | 106d | 148d | 165d | 196d | |
| Days payables outstanding | 93d | 81d | 89d | 84d | 92d | |
| Operating cycle | 163d | 138d | 184d | 193d | 220d | |
| Cash conversion cycle | 70d | 57d | 95d | 109d | 127d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+17.8%EV / Sales ▲+17.8%EV / EBITDA ▼-29.7%EV / Op. cash flow ▼-0.914Earnings yield ▼-0.006
Profitability
Return on equity ▼-0.379Return on assets ▲+0.006Return on invested capital ▲+0.002Return on capital employed ▼-0.064Operating ROA ▼-0.018Income quality ▼-0.036Tax burden 0.000
Efficiency
Days sales outstanding ▲+19.658Days payables outstanding ▲+11.767Operating cycle ▲+24.695Cash conversion cycle ▲+12.928Capex / Sales ▼-0.007R&D / Sales ▼-0.002
Balance-sheet strength
Current ratio ▲+0.015Net debt / EBITDA ▼-0.444Working capital ▲+412605.000Invested capital ▲+1605956.000Intangibles / Total assets ▼-0.027
Change over 5 years
Valuation
Market cap ▼-72.7%EV / Sales ▼-64.0%EV / EBITDA ▲+89.5%EV / Op. cash flow ▲+7.515Earnings yield ▼-1.125
Profitability
Return on equity ▲+0.779Return on assets ▼-0.131Return on invested capital ▼-0.267Return on capital employed ▼-0.376Operating ROA ▼-0.179Income quality ▼-0.450Tax burden ▼-0.015
Efficiency
Days sales outstanding ▼-69.434Days payables outstanding ▲+0.643Operating cycle ▼-56.654Cash conversion cycle ▼-57.297Capex / Sales ▼-0.015R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.328Net debt / EBITDA ▲+5.760Working capital ▼-9788513.000Invested capital ▲+6141264.000Intangibles / Total assets ▲+0.106
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-27 Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels Digital subscription platform brings together the Company''s proprietary consumer health products across consumer (B2C) and corporate (B2B) channels Customers can begin through one of three paths: a free nutritionist consultation, an AI-powered assistant, or building their own package Corporate offering supports employee wellness programs and corporate gifting through multi-recipient management, tiered volume pricing, centralized billing, and dedicated account management Future platform enhancements are expected to include AI-driven personalization and the potential integration of at-home testing and diagnostic kits Platform builds on the U.
- 2026-07-27 Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels Digital subscription platform brings together the Company''s proprietary consumer health products across consumer (B2C) and corporate (B2B) channels Customers can begin through one of three paths: a free nutritionist consultation, an AI-powered assistant, or building their own package Corporate offering supports employee wellness programs and corporate gifting through multi-recipient management, tiered volume pricing, centralized billing, and dedicated account management Future platform enhancements are expected to include AI-driven personalization and the potential integration of at-home testing and diagnostic kits Platform builds on the U.S. subscription launch of NOOR Collagen, which has delivered an early repeat purchase rate above 60% CHICAGO, July 27, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it is actively developing a flexible, technology-driven subscription platform for its consumer health products, representing a significant step in the Company''s broader technology-driven transformation. Designed around customer choice, the platform will allow customers to begin with a free consultation with a nutritionist, engage with an AI-powered assistant, or select products and build their own package.
- 2026-07-20 Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are distributed across Albania and recommended by doctors and healthcare professionals, supporting broad consumer access Expansion builds on the partnership launched in April 2025 and reflects Sky Premium Life''s continued global growth CHICAGO, July 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced an expansion of its partnership with Pharma Cell for the distribution of its Sky Premium Life brand in Albania. Building on the partnership the companies launched in April 2025, and reflecting the strong reception of Sky Premium Life in the Albanian market, the Company anticipates that orders under the expanded relationship will exceed 54,000 units on an annualized basis, with average monthly orders already exceeding 4,500 units.
- 2026-07-17 Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases CHICAGO, July 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share. The Company has now repurchased a total of 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 million.
- 2026-07-16 Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases CHICAGO, July 16, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 250,000 shares of its common stock in the open market at an average price of approximately $0.2782 per share. The Company has now repurchased a total of 4,838,000 shares for approximately $1.04 million under its previously announced share repurchase program of up to $5 million.
- 2026-07-15 Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases CHICAGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 100,000 shares of its common stock in the open market at an average price of approximately $0.
- 2026-07-15 Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases CHICAGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 100,000 shares of its common stock in the open market at an average price of approximately $0.2928 per share. The Company has now repurchased a total of 4,588,000 shares for approximately $970,000 under its previously announced share repurchase program of up to $5 million.
- 2026-07-14 Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases CHICAGO, July 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 133,000 shares of its common stock in the open market at an average price of approximately $0.298 per share. The Company has now repurchased a total of approximately 4,488,000 shares for approximately $941,000 under its previously announced share repurchase program of up to $5 million.
- 2026-07-13 Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 215,000 shares of its common stock in the open market at an average price of approximately $0.325 per share. The Company has now repurchased a total of 4,355,000 shares for approximately $901,000 under its previously announced share repurchase program of up to $5 million.
- 2026-07-13 Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in Greece Five-year agreement expected to contribute to revenue and cash-flow visibility As a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece''s national health insurance system, broadening its potential reach DIABIT-IS X is a generic alternative to Merck''s Januvia, which with Janumet generated approximately $4.